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Association between smoking, outcomes, and early
clopidogrel use in patients with acute coronary
syndrome: Insights from the Global Registry of Acute
Coronary Events
Matthew Sibbald, MD,a,h Andrew T. Yan, MD,a,h Wei Huang, MS,b,h Keith A. A. Fox, MB, ChB,c,h
Joel M. Gore, MD, PhD,b,h Ph. Gabriel Steg, MD,d,h Kim A. Eagle, MD,e,h David Brieger, MB, BS, PhD, f,h
Gilles Montalescot, MD, PhD,g,h and Shaun G. Goodman, MD, MSca ,h Toronto, Ontario; Worcester, MA;
Edinburgh, United Kingdom; Paris, France; Ann Arbor, MI; and Sydney, AustraliaBackground Smoking induces CYP1A2, thereby enhancing clopidogrel conversion to its active metabolite. We sought
to determine the association between clopidogrel use and clinical outcomes in smokers versus nonsmokers with a broad
spectrum of acute coronary syndrome (ACS).
Methods We examined the association between early clopidogrel use in-hospital and 6-month outcomes among 44,426
patients with ACS in relation to smoking status in the Global Registry of Acute Coronary Events. We tested for heterogeneity of
clopidogrel effect among smokers versus nonsmokers in separate multivariable models that adjusted for (1) established
prognosticators in the Global Registry of Acute Coronary Events risk score and (2) independent predictors of major bleeding.
Results Rates of in-hospital mortality, death/myocardial infarction, and major bleeding were 4.3%, 5.9%, and 2.5%,
respectively. Current smokers (n = 12,149) were more likely to be younger men without documented vascular disease; had
lower rates of hypertension, hyperlipidemia, and diabetes; and more frequently presented with ST elevation (all P b .0001).
Early clopidogrel use (55%) was associated with a reduction in the composite endpoint of mortality and myocardial infarction
both in-hospital and at 6 months among current smokers and nonsmokers. There was no interaction between current smoking
and clopidogrel use for ischemic endpoints. Major bleeding associated with early clopidogrel use was actually lower among
current smokers compared with nonsmokers.
Conclusions Despite prior observations of smoking-enhanced clopidogrel effects, early clopidogrel use among smokers
presenting with ACS compared with nonsmokers was not independently associated with a greater reduction in cardiovascular
events. In contrast with nonsmokers, clopidogrel use among smokers was not associated with excess bleeding, perhaps
because of unmeasured confounders. (Am Heart J 2010;160:855-61.)Background
Clopidogrel is metabolized by cytochrome P450s to its
active compound that irreversibly binds platelet P2Y12
receptors. Recent data suggest that current smokers may
have enhanced P2Y12 blockade after clopidogrel from
up-regulation of its metabolizing CYP1A2 enzyme,
thereby augmenting its clinical effects.1-4 In the CLARI-
TY-TIMI 28 trial of patients presenting with ST elevationFrom the aDivision of Cardiology, Canadian Heart Research Center and Terrence Donnelly
Heart Center, St Michael's Hospital, University of Toronto, Toronto, Ontario, bDepartment
of Medicine, University of Massachusetts Medical School, Worcester, MA, cDivision of
Medical & Radiological Sciences, Cardiovascular Research, The University of Edinburgh,
Edinburgh, United Kingdom, dINSERM U-698, Université Paris 7, AP-HP, Centre
Hospitalier Bichat-Claude Bernard, Paris, France, eUniversity of Michigan Health System,
Ann Arbor, MI, fCoronary Care Unit, Concord Hospital, Sydney, Australia, and gInstitut de
Cardiologie, Bureau 2-236, Centre Hospitalier Universitaire Pitié-Salpêtrière, AP-HP, 47
Blvd de l'Hôpital, 75013, Paris, France.myocardial infarcts, smokers treated with clopidogrel had
better clinical outcomes.5 Similarly, among patients at
high vascular risk in the CHARISMA trial, a reduction in
mortality associated with clopidogrel use was only seen
among smokers in a post hoc analysis.6 No data about this
interaction exist in patients across the full spectrum of
acute coronary syndrome (ACS) in a nonclinical trial,
“real-world” setting.hOn behalf of the Global Registry of Acute Coronary Events (GRACE/GRACE2)
investigators. A list of participating GRACE/expanded GRACE (GRACE2) investigators
may be found in the Am Heart J 2009:158:193-201.e1-5.
Submitted June 1, 2010; accepted July 21, 2010.
Reprint requests: Shaun G. Goodman, MD, MSc, St Michael's Hospital, Division of
Cardiology, 30 Bond Street, Room 6-034 Queen, Toronto, Ontario, Canada M5B 1W8.
0002-8703/$ - see front matter
© 2010, Mosby, Inc. All rights reserved.
doi:10.1016/j.ahj.2010.07.026
856 Sibbald et al
American Heart Journal
November 2010The primary objective of this observational study is to
examine the association between clopidogrel use and in-
hospital outcomes (death, in-hospital myocardial infarc-
tion [MI], and major bleeding) among patients with ACS
in relation to smoking status before hospitalization. We
hypothesize that clopidogrel use is independently asso-
ciated with a greater reduction in adverse cardiovascular
events but a higher risk of bleeding among smokers
compared with non-smokers.Methods
The details and rationale for the Global Registry of Acute
Coronary Events (GRACE) and expanded GRACE have been
published elsewhere.7,8 In brief, 247 hospitals from 30 countries
participated in a prospective observational registry of patients
with ACS. Patients were eligible if they were older than 18 years
with a presumptive diagnosis of ACS, defined as symptoms
compatible with cardiac ischemia, and at least one of the
following: positive biomarkers of myocardial necrosis, electro-
cardiographic (ECG) changes consistent with ACS, or docu-
mented evidence of coronary artery disease. Patients were
classified as current smokers if they reported cigarette smoking
in the month before admission, former smokers if they had
reported quitting more than 1 month before admission, and
nonsmokers if they reported never smoking. Cigar and pipe
smoking was not included. Early medication use was defined as
medication given within 24 hours of presentation to hospital.
Patients with ACS precipitated by or concomitant with trauma
or surgery were excluded. Demographics, clinical presentation,
laboratory results, relevant treatment, and in-hospital outcome
were recorded on case report forms. Ethics approval was sought
from relevant hospital or institutional boards where required.
Forty-five thousand eight-hundred fourteen patients were
enrolled from 1999 to 2007 using case report forms that
collected data on clopidogrel use within 24 hours of hospital
presentation. Three percent were excluded because data on
early clopidogrel use (n = 389) or smoking history (n = 999)
were missing, resulting in a final cohort of 44,426 patients with a
final ACS diagnosis. Six-month follow-up data were available for
30,580 of these patients. Patients were divided into 4 groups
based on their prehospitalization smoking status and early
clopidogrel use. Former smokers were considered as non-
smokers for the purpose of this analysis.
Outcomes assessed included death and reinfarction both in-
hospital. Reinfarction was defined as a clinically documented
event with re-elevation of creatine kinase-MB (CK-MB) above
the upper limit of normal (ULN) and an increase of at least 50%
more than the previous value 24 hours after the index MI. If
CK-MB was unavailable, CK reelevation of ≥2 times the ULN
with an increase of 25% more than the previous value or ≥ 1.5
times the ULN with an increase of 50% more than the previous
value was required. After percutaneous coronary intervention
(PCI), CK-MB needed to be ≥3 times the ULN and at least 50%
increased from previous. After coronary artery bypass graft
(CABG), both CK-MB elevation of ≥3 times the ULN and at least
50% increase from previous as well as ECG changes consistent
with MI were required.9
Unadjustedoddsratios(ORs)forearlyclopidogeluseversusnon-
use stratifiedby smokingstatuswerecalculated foreachoutcome.Continuous data are summarized as medians with interquartile
ranges, and categorical data are reported as frequencies and
percentages. χ2 and Kruskal-Wallis tests were used to compare
categorical and continuous variables, respectively.
Multivariable analysis using a logistic regression model was
constructed using smoking status and early clopidogrel use as
covariates. An interaction term of smoking status and early
clopidogrel use was added. A first model adjusted for all
independent predictors of in-hospital death in the GRACE risk
score.10,11 Because medication use varied significantly among
early clopidogrel users compared with nonusers, a second model
was constructed that also adjusted for early medication use. A
third model was constructed for major bleeding controlling for
known independent predictors of bleeding, including age,
gender, history of bleeding, systolic blood pressure, creatinine,
in-hospital cardiac catheterization, in-hospital percutaneous
coronary intervention, low-molecular-weight heparin use, throm-
bolytic use, and glycoprotein IIb/IIIa inhibitor use.12
A propensity score was devised for the probability of
clopidogrel use adjusted for independent predictors of in-
hospital mortality in the GRACE risk score and medical history
(angina, MI, congestive heart failure, coronary artery disease,
PCI, CABG, hypertension, dyslipidemia, prosthetic valve re-
placement, atrial fibrillation, transient ischemic attack/stroke,
diabetes, renal insufficiency, major surgery, and major bleed-
ing). The propensity score (probability of clopidogrel use) was
categorized into quintiles. Matching of clinical characteristics
between patients receiving clopidogrel and those not receiving
clopidogrel across quintiles of propensity score was verified. In
an ancillary analysis to examine the relationship clopidogrel use,
smoking and outcomes, additional logistic regression models
were constructed to adjust for independent predictors (of
GRACE risk score or major bleeding), medication use, and
propensity quintiles. We performed statistical analyses using SAS
version 9.1 (SAS Inc, Cary, NC).
This research was supported by an unrestricted grant from
Sanofi-Aventis, Paris, France. The sponsor had no involvement in
the conception or design; collection, analysis, and interpretation
of data; writing, review, or approval of the manuscript; and
decision to submit the manuscript for publication.Results
Of the 44,426 patients with ACS in the study cohort,
12,149 (27%) were current smokers. Overall, early use of
clopidogrel was 55% and more common among current
smokers than non-smokers (61% vs 53%). Current smokers
were younger, more likely to be male and less likely to
have hypertension, diabetes, or known atherosclerotic
disease (prior angina, MI, coronary revascularization,
congestive heart failure, transient ischemic attacks, and
strokes). Smokers were more likely to present with ST
elevation and had lower GRACE risk scores (Table I).
Smokers were more often treated with fibrinolysis,
angiography, and angioplasty (Table II). Rates of aspirin,
β blocker, statin, and glycoprotein IIb/IIIa inhibitor use
were higher among those who received clopidogrel.
Table I. Baseline characteristics of 4 groups
Nonsmokers (n = 32 277) Smokers (n = 12 149)
P (4-group
comparisons)
No early
clopidogrel use
Early clopidogrel
use
No early
clopidogrel use
Early clopidogrel
use
n n n n
Age (y)⁎ 15 072 72 (62, 80) 17 094 69 (59, 77) 4 779 58 (50, 67) 7 326 56 (49, 64) b.001
Female sex 15 052 40.5% 17 123 33.4% 4 772 23.8% 7 326 21.4% b.001
Hypertension 15 046 68.8% 17 130 67.4% 4 767 52.9% 7 343 48.5% b.001
Dyslipidemia 15 005 46.5% 17 117 55.2% 4 766 42.8% 7 335 46.5% b.001
Diabetes 15 076 28.9% 17 133 28.0% 4 769 18.5% 7 333 16.2% b.001
History
Angina 15 066 56.6% 17 130 48.4% 4 767 49.5% 7 343 34.9% b.0001
MI 15 065 35.0% 17 123 31.7% 4 771 25.8% 7 337 20.9% b.0001
Peripheral vascular disease 15 035 15.6% 17 125 23.8% 4 768 11.7% 7 325 14.7% b.0001
CABG 15 054 15.0% 17 125 14.6% 4 773 6.5% 7 323 6.0% b.0001
CHF 14 997 16.3% 17 065 9.1% 4 768 6.5% 7 321 3.3% b.0001
TIA/stroke 15 016 10.2% 17 115 8.5% 4 763 6.0% 7 325 4.9% b.0001
Peripheral vascular disease 15 014 9.9% 17 102 9.1% 4 762 9.3% 7 323 8.0% .0001
Bleeding 15 039 1.8% 17 112 1.2% 4 765 1.2% 7 327 0.7% b.0001
Presenting physical exam
Systolic blood pressure
mm Hg⁎
14 881 140 (120, 160) 16 719 140 (122, 160) 4 699 137 (120, 156) 7 116 138 (120, 157) b.001
Diastolic blood pressure
(mm Hg)⁎
14 853 80 (69, 90) 16 690 80 (70, 90) 4 694 80 (70, 90) 7 107 80 (70, 92) b.001
Heart rate (beat/min)⁎ 14 868 78 (66, 92) 16 681 75 (64, 88) 4 690 77 (65, 90) 7 101 76 (65, 89) b.001
Killip class 14 760 16 815 4 715 7 204
I 78.6% 85.7% 85.6% 89.4% b.001
II 14.9% 10.4% 9.8% 7.9%
III 5.2% 3.3% 3.4% 1.9%
IV 1.3% 0.7% 1.3% 0.9%
Presenting ECG and
cardiac biomarkers
ST deviation on presentation 15 110 49.2% 17 167 51.4% 4 791 59.0% 7 358 64.1% b.001
T wave inversion
on presentation
15 110 27.5% 17 167 26.0% 4 791 28.9% 7 358 24.1% b.001
Positive initial biomarker 14 726 43.9% 16 710 50.0% 4 667 44.9% 7 116 53.2% b.001
Creatinine (μmol/L)⁎ 14 010 97 (79, 114) 16 315 88 (79, 114) 4 301 88 (79, 106) 6 938 88 (70, 97) b.001
GRACE risk score⁎ 13 131 137 (110, 165) 15 166 131 (108, 156) 4 034 118 (96, 144) 6 414 116 (95, 139) b.001
Final diagnosis 15 110 17 167 4 791 7 358
STEMI 27.9% 35.1% 40.6% 50.9% b.001
NSTEMI 34.0% 37.3% 28.4% 30.9%
Unstable angina 38.1% 27.7% 31.0% 18.2%
CHF Congestive heart failure; TIA transient ischemic attack; STEMI ST elevation myocardial infarction; and NSTEMI non-ST elevation myocardial infarction.
⁎Median (25th 75th percentiles).
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Volume 160, Number 5The risk of in-hospital death or (re)infarction adjusted for
GRACE risk score and smoking status was lower among
patients treated with clopidogrel (OR 0.72, 95% CI 0.65-
0.79, P b .0001); there was a lower adjusted risk of in-
hospital death (OR 0.49, 95% CI 0.43-0.55, P b .0001) but
not reinfarction (OR 1.08, 95% CI 0.92-1.26, P = .39).
When stratified by smoking status, no significant
interaction between early clopidogrel use and smoking
status was found (Table III). Similarly, no interaction was
found in the subanalysis of 43,972 patients who survived
the first 24 hours of hospitalization or the 17,767 patients
who underwent PCI during the index hospitalization
after adjusting for the independent predictors of the
GRACE risk score. In propensity score analysis, clopido-grel was also associated with a reduction in the
composite risk of death and reinfarction in-hospital and
at 6 months across all quintiles. In the propensity model,
the interaction term for clopidogrel and smoking was
also not significant for the composite endpoint of death
and reinfarction (P = .70 in-hospital and P = .99 at 6
months). P values for the interaction terms for in-hospital
death and reinfarction were .07 and .86, respectively.
Similarly, at 6 months, P values for the interaction terms
were not significant (P = .79 and P = .99 for death and
death/(re-)MI, respectively).
Overall, the rate of in-hospital major bleeding was low
at 2.8%. The association between early clopidogrel use
and major bleeding differed by smoking status.
Table II. Inhospital medical and invasive management
Nonsmokers (n = 32 277) Smokers (n = 12 149)
P (4-group
comparisons)
No early
clopidogrel use
Early
clopidogrel use
No early
clopidogrel
use
Early
clopidogrel
use
n n n n
Medication use within the first 24 h:
Aspirin 15 101 85.9% 17 158 91.2% 4 786 90.4% 7 357 93.1% b.0001
β blocker 15 007 68.3% 17 042 77.3% 4 747 71.0% 7 312 79.1% b.0001
ACE inhibitor 15 017 46.8% 17 029 52.3% 4 767 42.7% 7 315 51.7% b.0001
Angiotensin receptor blocker 14 918 4.7% 16 895 6.6% 4 735 2.8% 7 247 2.8% b.0001
Calcium channel blocker 14 941 17.3% 16 959 16.7% 4 745 11.2% 7 271 9.2% b.0001
Statin 15 047 41.1% 17 106 66.9% 4 779 41.1% 7 333 68.9% b.0001
Unfractionated heparin 14 983 35.1% 16 943 37.8% 4 745 37.3% 7 272 42.0% b.0001
Enoxaparin 15 009 40.5% 16 973 49.7% 4 754 38.6% 7 265 49.4% b.0001
Glycoprotein IIb/IIIa inhibitor 10 109 7.4% 15 796 23.8% 3 122 10.2% 6 831 33.5% b.0001
Fibrinolytics 14 927 10.7% 16 934 8.7% 4 723 22.4% 7 260 16.2% b.0001
Inhospital cardiac procedures:
Coronary angiography 15 008 39.0% 17 092 78.6% 4 767 48.6% 7 333 86.0% b.0001
PCI 15 041 13.1% 17 109 57.2% 4 772 20.8% 7 330 68.5% b.0001
Coronary artery bypass surgery 14 986 7.1% 16 964 3.6% 4 743 7.0% 7 262 3.3% b.0001
ACE indicates angiotensin-converting enzyme.
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November 2010Clopidogrel use was independently associated with
bleeding among non-smokers but not among smokers in
both multivariable models (Table III). However, when
correcting for quintiles of propensity score, major
bleeding was increased among all early clopidogrel
users (OR 1.27, 95% CI 1.07-1.51, P = .007).Discussion
This is the first observational study to examine the
association between clopidogrel use and outcomes
among patients with ACS in relation to smoking status
in a non-clinical trial, real-world setting. The key findings
are as follows: (1) early clopidogrel use was associated
with a decreased event rate among patients with ACS, (2)
there was no significant interaction between early
clopidogrel use in patients with ACS and smoking status
on in-hospital mortality or reinfarction, (3) early clopido-
grel use among patients with ACS did not result in a large
increase in major bleeding, and (4) there was a significant
interaction between early clopidogrel use in patients with
ACS and smoking status with respect to major bleeding.
Early clopidogrel use associated with a decreased
event rate among patients with ACS
The associated lower incidence of nonfatal MI and
mortality among patients with ACS with early clopidogrel
use reported in this study is greater than that previously
reported. In the CURE trial, early use of clopidogrel in
patientswithnon-STelevationACS resulted ina20% relative
risk reduction of a composite endpoint of death, recurrent
MI, and stroke after 1 year.13 A similar 31%odds reduction incomposite endpoint of angiographic artery occlusion, in-
hospital death, and reinfarctionwas seen inpatientswith ST
elevationACSwith the additionof clopidogrel to aspirin and
fibrinolytic therapy in the CLARITY trial.14 In the largest
randomized study, the ClOpidogrel and Metoprolol in
Myocardial Infarction Trial (COMMIT), clopidogrel usewas
associated with a 9% reduction in death, reinfarction, and
stroke along with a 7% proportional reduction in death
among patients with ACS at 2 weeks.15 The augmented
“treatment” effect in our observational cohort is likely a
result of residual confounding in patients receiving early
clopidogrel in a non-randomized setting. A more modest
and consistent reduction in endpoints associated with
clopidogrel use was observed in the logistic regression
modeling of the data with corrections for GRACE risk
variables and medication use.
Lack of interaction between smoking and early
clopidogrel use in patients with ACS
Smoking is a potent inducer of cytochrome 1A216-18 that
has been reported to modify in vivo drug levels and
efficacy.5,19-21 This up-regulation of cytochrome 1A2 may
lead to enhanced metabolism of clopidogrel to its active
metabolite. Bliden et al showed significantly less platelet
aggregation and adenosine diphosphate-induced platelet
glycoprotein IIb/IIIa expression among smokers who
received loading doses of clopidogrel compared with
non-smokers at the time of angioplasty. The clinical
implications of this effect were explored by Desai et al in
a post hoc analysis of the Clopidogrel as Adjunctive
Reperfusion Therapy (CLARITY)–Thrombolysis in Myocar-
dial Infarction (TIMI) 28 trial. Smoking 10 or more
Table III. Events with and without early clopidogrel use by smoking status
Inhospital
outcomes
Nonsmoker Current smoker
P for
interaction
(multivariable
model)
No
clopidogrel
n (%)
Clopidogrel
n (%)
Adjusted OR
(95% CI, P)
No
clopidogrel
n (%)
Clopidogrel
n (%)
Adjusted OR
(95% CI, P)
Death 1 108 (7.4%) 482 (2.8%) 0.50
(0.44-0.56, P b .0001)⁎
216 (4.5%) 119 (1.6%) 0.44
(0.34-0.58, P b .0001)⁎
.43⁎
0.48
(0.34-0.68, P b .0001)†
0.60
(0.51-0.70, P b .0001)†
.07†
Death/MI 1 289 (8.6%) 828 (4.8%) 0.71
(0.64-0.79, P b .0001)⁎
253 (5.3%) 247 (3.4%) 0.77
(0.62-0.95, P = .013)⁎
.50⁎
0.77
(0.60-0.99, P b .04)†
0.80
(0.70-0.90, P b .0004)†
.70†
Major
bleeding
338 (2.3%) 527 (3.1%) 1.63
(1.41-1.90, P b .0001)⁎
94 (2.0%) 144 (2.0%) 1.002
(0.752-1.336, P = .9873)⁎
.0003⁎
1.179
(0.986-1.409, P = .071)‡
1.024
(0.722-1.450, P = .90)‡
.02‡
Death at
6 mo
699 (6.7%) 425 (3.6%) 0.64
(0.56-0.74, P b .0001)⁎
118 (3.4%) 96 (1.9%) 0.67
(0.49-0.90, P b .009)⁎
.79⁎
0.74
(0.62-0.87, P = .0004)†
0.65
(0.44-0.97, P = .0333)†
.87†
Death/MI
at 6 mo
70 (5.2%) 271 (4.0%) 0.78
(0.69-0.87, P b .0001)⁎
24 (3.4%) 111 (3.2%) 0.74
(0.59-0.94, P = .01)⁎
.99⁎
0.79
(0.68-0.90, P = .0006)†
0.69
(0.51-0.92, P = .01)†
.91†
⁎Adjusted for all independent predictors of in-hospital death in GRACE risk score.
†Adjusted for all independent predictors of in-hospital death in GRACE risk score, medication use in the first 24 hours (aspirin, β blockers, angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, calcium channel blockers, unfractionated heparin, low-molecular-weight heparins, statins, and glycoprotein IIb/IIIa inhibitors), and propensity
score quintiles.
‡Adjusted for factors significantly associated with major bleeding based on Moscucci et al.13
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Volume 160, Number 5cigarettes a day was associated with a near doubling in
clopidogrel-related reduction of 30-day death and reinfarc-
tion in patients with ST elevationMI.5 In a post hoc analysis
of the CHARISMA trial, a significant interaction between
smoking status and clopidogrel existed.6 In this placebo-
controlled trial of patients at high cardiovascular risk
followed on average for 28 months, randomization to
clopidogrel was associated with a significant reduction in
mortality and increase in major bleeding only among
smokers, in contrast with non-significant effects in non- or
former smokers.
The findings in the current analysis of the GRACE
registry differ from the aforementioned clinical trial data.
Although we found no convincing interaction between
smoking status and early clopidogrel use, there was a
borderline significant interaction term for in-hospital
death in our model corrected for GRACE risk score,
medication use, and propensity quintiles. It is possible
that the interaction between smoking and clopidogrel is
less relevant in a less selected group of patients. However,
follow-up was shorter and less complete than in either the
CHARISMA or CLARITY-TIMI 28 trials.5,6 In addition,
because clopidogrel-related platelet inhibition has been
linked to stent-related outcomes,22,23 differing rates of
angiography and angioplasty in these 2 studies may also
partly account for this difference. Lastly, quantification of
smoking or clopidogrel loading dose was not recorded inGRACE. Significant loading doses might have overcome
varied metabolism, especially among light smokers, and
may not have reached the necessary threshold for a
demonstrable interaction. Nonetheless, the lack of
interaction in this large unselected real-world population
suggests that the effects of clopidogrel may not be
significantly altered by smoking status in a broad ACS
patient population.Clopidogrel-related bleeding
Clopidogrel was associated with a 1.0% absolute
increase in CURE major bleeding over 9 months in the
CURE trial.11 In CLARITY, no significant increase in TIMI
major bleeding was detected with clopidogrel use during
1-month follow-up; however, the duration of blinded,
placebo-control treatment was a maximum of 8 days.13-15
Similarly, no increase in major bleeding (defined as
bleeding that was fatal, intracerebral, or requiring
transfusion) was detected during a median follow-up of
14 days in COMMIT.13-15 In this large real-world registry
analysis, early clopidogrel use was associated with a less
than 1% increase in major bleeding in hospital. Among
smokers, rates of major bleeding were the same among
those who used and did not use clopidogrel. This may be
because of short follow-up and incomplete statistical
correction of bleeding risk factors among smokers. This
860 Sibbald et al
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November 2010evidence supports the safety profile demonstrated in the
more selected patients enrolled in randomized trials.
Limitations
Several limitations of the current study need be
considered. The duration and degree of the effects of
smoking on clopidogrel metabolism is unknown. We
could not control for the time from pre-hospital
smoking to post-admission clopidogrel administration.
Furthermore, we are unable to quantify the number of
cigarettes smoked per day that may have been below
the threshold of 10 cigarettes per day noted by Desai et
al.6 Lastly, we do not have data on smoking status post-
admission; for example, a substantive decrease in
smoking rates could make a potential interaction more
difficult to detect at 6-month follow-up.
As a large registry-based analysis, uncorrected con-
founders may still exist despite adjustment for all known
prognostic factors. In particular, non-smokers in the
GRACE were a higher risk group of patients who may
derive greater absolute therapeutic benefit from clopido-
grel. Although we attempted to correct for these
demographic differences, we recognize the limitations
of unmeasured confounders in our registry database. We
also recognize the issue of loss to follow-up at 6 months in
our data set. It is also possible that the interaction
between smoking and clopidogrel use is more significant
in ST elevation ACS where treatment with coronary
stenting is particularly common and the role of clopido-
grel is paramount. In contrast with the clinical trial setting
of CLARITY, the patients in GRACE were older with a
greater proportion of women and a relatively lower
proportion of patients who smoked; thus, our popula-
tion may differ with respect to underlying genetic
cytochrome polymorphisms with resultant differences
in susceptibility to the pharmacokinetic alterations
because of smoking.2,4
In summary, this observational study of patients with
ACS suggests similar efficacy and safety of early clopido-
grel use in smokers and non-smokers. We speculate that
the previously reported interaction between smoking and
clopidogrel use may not be as pronounced in the
management of a broader spectrum of ACS in the real-
world setting.Funding
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